Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: laser photocoagulation Clear all
Completed Phase 1 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00027287
View directory record Official record
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

NCT04101721
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
aflibercept, laser photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 6, 2026, 3:14 AM EDT
Completed No phase listed Observational

The Course of Response to Focal Photocoagulation for DME

NCT00442156
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Laser photocoagulation
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

NCT00606138
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

NCT02506049
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
S-LPC:Selective Laser Photocoagulation
Device
Lead sponsor
University of Tennessee
Other
Eligibility
16 Weeks to 27 Weeks · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 6, 2026, 3:14 AM EDT
Terminated Not applicable Interventional Results available

Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema

NCT02032238
View directory record Official record
Conditions
Clinically Significant Macular Edema
Interventions
laser photocoagulation
Device
Lead sponsor
OD-OS GmbH
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

NCT00815360
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT04278417
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 6, 2026, 3:14 AM EDT
Withdrawn Not applicable Interventional

Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation

NCT06022510
View directory record Official record
Conditions
Twin Monochorionic Diamniotic Placenta
Interventions
Fetoscopy Sets for Anterior and Posterior Placentas
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 6, 2026, 3:14 AM EDT
Not yet recruiting Not applicable Interventional

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses

NCT06084247
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
Curved KARL STORZ fetoscope, Conventional Scopes
Device
Lead sponsor
Jimmy Espinoza
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 3 Interventional

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

NCT00105404
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 3:14 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2005 · Synced Sep 6, 2026, 3:14 AM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

NCT00841373
View directory record Official record
Conditions
Retinal Ischemia
Interventions
Panretinal Photocoagulation, Panretinal Photocoagulation and intravitreal injection of ranibizumab
Procedure
Lead sponsor
Southern New England Retina Associates
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

NCT00464685
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham injection, Laser Photocoagulation
Drug · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome

NCT02122328
View directory record Official record
Conditions
Twin Twin Transfusion Syndrome
Interventions
Sequential laser photocoagulation of communicating vessels., Selective laser photocoagulation of communicating vessels
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
642 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation

NCT02995629
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy - High Risk
Interventions
laser indirect ophthalmoscopy pan retinal photocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Anti-VEGF Treatment for Prevention of PDR/DME

NCT02634333
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

NCT02569892
View directory record Official record
Conditions
Macular Degeneration, Retinal Drusen
Interventions
Pascal Retinal Laser Photocoagulator
Device
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 6, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 6, 2026, 3:14 AM EDT